LLY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LLY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eli Lilly and Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2,074 Mil. Eli Lilly and Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $29,045 Mil. Eli Lilly and Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $14,240 Mil. Eli Lilly and Co's debt to equity for the quarter that ended in Sep. 2024 was 2.19.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Eli Lilly and Co's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Eli Lilly and Co was 6.64. The lowest was 0.32. And the median was 1.63.
The historical data trend for Eli Lilly and Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | 5.88 | 2.94 | 1.88 | 1.53 | 2.34 |
Eli Lilly and Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-Equity | Get a 7-Day Free Trial | 1.80 | 2.34 | 2.05 | 2.13 | 2.19 |
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Eli Lilly and Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (6904.5 | + | 18320.8) | / | 10771.9 | |
= | 2.34 |
Eli Lilly and Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (2074.3 | + | 29045.4) | / | 14240 | |
= | 2.19 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (NYSE:LLY) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Eli Lilly and Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Lilly Endowment Inc | 10 percent owner | 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208 |
Donald A Zakrowski | officer: Chief Accounting Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Johna Norton | officer: Senior VP, Global Quality | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Alonzo Weems | officer: SVP, ERM & CECO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Patrik Jonsson | officer: SVP and Pres., Lilly Bio-Meds | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Anne E. White | officer: SVP & Pres-Lilly Oncology | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Eric Dozier | officer: EVP, HR & Diversity | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jackson P Tai | director | |
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Marschall S Runge | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Naarden Jacob Van | officer: SVP, CEO LoxoONC, Pres LlyONC | C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Diogo Rau | officer: SVP & CIDO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Edgardo Hernandez | officer: SVP & Pres., Mfg. Operations | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Kimberly H Johnson | director | C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005 |
Anat Ashkenazi | officer: SVP & CFO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
From GuruFocus
By PRNewswire • 08-16-2024
By PRNewswire • 08-13-2024
By Sydnee Gatewood • 08-12-2024
By GuruFocus Research • 08-07-2024
By PRNewswire • 07-08-2024
By PRNewswire • 08-08-2024
By PRNewswire • 08-16-2024
By GuruFocus Research • 08-09-2024
By PRNewswire • 09-25-2024
By PRNewswire • 09-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.